Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remineralizing Agents vs Fluoride Gel for White Spot Lesions in Children
NCT06821724Completed
- Start
- Dec 2024
- Primary completion
- Jan 2025
- Modality
- Nanoparticles, Device-based Delivery, Hydrogel Systems
- Countries
- 1
01
Overview
Randomised, open-label trial of casein phosphopeptide-amorphous calcium phosphate and nanohydroxyapatite in White spot lesion (WSL) (5 arms). Primary endpoint: Assessment of color change at 6 weeks. Started Dec 2024; status: completed.
02
Drugs
casein phosphopeptide-amorphous calcium phosphatenanohydroxyapatite
03
Conditions
White spot lesion (WSL)
Beyond the preview
Go deeper on NCT06821724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821724.